Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE: Tiragolumab + Ivonescimab in Advanced Lung Squamous Cell Carcinoma
NCT07038915Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
01
Overview
A Phase 2 trial of tiragolumab, ivonescimab in squamous cell carcinoma of the lung (LSCC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jul 2025; status: withdrawn.
02
Drugs
tiragolumabivonescimab
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT07038915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038915.